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This prospective study dem-
onstrates that hypofractio-
nated radiation therapy
delivered with a plan of the
day approach is well toler-
ated in patients unfit for
radical bladder cancer treat-
ment. It provides opportunity
for local disease and symp-
tom control in patients for
whom cystectomy, trimo-
dality, or daily radiation
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http://dx.doi.org/10.1016/j.ijrobp.2017.01.239Purpose and Objectives: We report on the clinical outcomes of a phase 2 study asses-
sing image guided hypofractionated weekly radiation therapy in bladder cancer pa-
tients unsuitable for radical treatment.
Methods and Materials: Fifty-five patients with T2-T4aNx-2M0-1 bladder cancer not
suitable for cystectomy or daily radiation therapy treatment were recruited. A “plan of
the day” radiation therapy approach was used, treating the whole (empty) bladder to
36 Gy in 6 weekly fractions. Acute toxicity was assessed weekly during radiation ther-
apy, at 6 and 12 weeks using the Common Terminology Criteria for Adverse Events
version 3.0. Late toxicity was assessed at 6 months and 12 months using Radiation
Therapy Oncology Group grading. Cystoscopy was used to assess local control at
3 months. Cumulative incidence function was used to determine local progression
at 1 at 2 years. Death without local progression was treated as a competing risk. Over-
all survival was estimated using the Kaplan-Meier method.
Results: Median agewas 86 years (range, 68-97 years). Eighty-seven percent of patients
completed their prescribed course of radiation therapy. Genitourinary and, FRCR, Radiotherapy and
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respectively. No grade 4 genitourinary or gastrointestinal toxicity was seen. Grade 3
late toxicity (any) at 6 and 12monthswas seen in 6.5% (2/31) and 4.3% (1/23) of patients,
respectively. Local control after radiation therapy was 92% of assessed patients (60% to-
tal population). Cumulative incidence of local progression at 1 year and 2 years for all
patients was 7% (95% confidence interval [CI] 2%-17%) and 17% (95% CI 8%-29%),
respectively. Overall survival at 1 year was 63% (95% CI 48%-74%).
Conclusion: Hypofractionated radiation therapy deliveredweekly with a plan of the day
approach offers good local control with acceptable toxicity in a patient population not
suitable for radical bladder treatment.  2017 The Author(s). Published by Elsevier
Inc. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).Introduction
The underuse of curative therapy in patients with muscle
invasive bladder cancer (MIBC) is well documented (1-3).
High cancer-specific mortality is particularly evident in
older patients, reflecting their poorer access to effective
treatment (2).
There is good evidence that symptomatic local disease
can be relieved for the duration of survival with hypo-
fractionated radiation therapy (21 Gy in 3 fractions on
alternate days) when either cystectomy or radical radiation
therapy is unsuitable (4). Inasmuch as local disease control
is related to total radiation therapy dose delivered, a higher
biological effective dose is anticipated to improve out-
comes (5, 6). Several retrospective studies report successful
treatment of MIBC with 30 to 36 Gy in 6 weekly fractions
(7-10). Each fraction of this regimen represents w17% of
the prescription dose, so a geographic miss could poten-
tially compromise tumor control and tolerability.
Image guided adaptive radiation therapy (IGRT) strategies
in bladder cancer show significant dosimetric gains for tumor
coverage and normal tissue sparing (11-15). Implementation
is therefore anticipated to improve local control and toxicity,
but prospective studies are lacking. Here we report on the
long-term clinical outcomes of “plan of the day” hypo-
fractionated radiation therapy in a nonrandomized phase 2
study in patients unsuitable for radical treatment.
Methods and Materials
Between January 2009 and March 2014, 55 patients with
pathologic evidence of MIBC who were unsuitable for cys-
tectomy or daily radiation therapy because of stage, comor-
bidity, or personal preferencewere recruited prospectively to
an institutional Clinical Research and Ethics Committee
approved protocol (NCT01000129; ISRCTN80815524).
Details of planning and plan selection have been previ-
ously presented and are summarized in Table E1 (available
online at www.redjournal.org) (12, 16). Normal tissue
constraints are given in Table E2 (available online at www
.redjournal.org). Treatment was delivered using planselection from a library of three 3-dimensional (3D)
conformal plans treating whole empty bladder to 36 Gy in 6
fractions over 6 weeks.
Acute toxicity was collected using the Common Ter-
minology Criteria for Adverse Events version 3.0 at base-
line, weekly during radiation therapy, and then at 6 and
12 weeks after the completion of treatment. Local response
was assessed at 3 months with cystoscopy and biopsy
where possible. Local response was defined as absence of
pathologic or clinical MIBC at cystoscopy, pathologic or
radiologic downstaging to noninvasive disease, or stable
radiologic disease.
Late toxicity was scored at 6 months and 12 months
using the Radiation Therapy Oncology Group (RTOG) late
radiation morbidity-scoring schema. Patients were subse-
quently followed up as clinically indicated, with cysto-
scopic surveillance and imaging where appropriate.
Overall survival was estimated using the Kaplan-Meier
method and was defined as time from start of radiation ther-
apy to death resulting from any cause. Surviving patients and
those lost to follow-up were censored at the last assessment
date. Cumulative incidence competing risk (CICR) method
was used to calculate local progression at 1 and 2 years. Local
progression was defined as interval from the start of radiation
therapy to disease relapse within the bladder (pathologic,
radiologic, or clinical). Death without local progression was
treated as a competing risk. CICR analysis was performed
using R version 3.3.1. All other analyses were carried out
using STATA v13.1 (StataCorp LP, TX).Statistical considerations
Sample size was calculated assuming the rate of local
control was no more than 40% at 3 months (null hypoth-
esis). Using a single-stage design with 1-sided a of 0.05
(assuming true rate of control is 60%), 56 patients were
estimated for 90% power. Considering expected loss to
follow-up before the 3-month evaluation, recruitment target
was set at 67 patients. The study closed before this because
of a competing study (HYBRID study; NCT01810757)
(17).
Table 1 Patient characteristics
Characteristic n
Age Median, 86 years (range, 68-97)
Sex
Male 31
Female 24
Stage at presentation*
T2N0M0 36
T3N0M0 11
T4N0M0 3
TanyN1-N3M0 3
TanyNanyM1 2
Histologic subtype
Transitional cell carcinomay 49
Squamous cell carcinoma 3
Adenocarcinoma 1
Other 2
Grade
Intermediate (grade 2) 1
High (grade 3) 52
Unknown 2
WHO performance status at baselinez
0 4
1 16
2 12
3 6
Unknown 17
Charlson comorbidity index (age adjusted)x
0 21 (0)
1 11 (0)
2 12 (0)
3 3 (2)
4 5 (18)
5 3 (35)
Number of fractions deliveredk
4 4
5 6
6 45
Assessment of response 3 months after radiation therapy
Cystoscopy 30
Radiology alone 6
Not assessed 19
Abbreviation: WHO Z World Health Organization.
* All patients were staged no more than 6 weeks before receiving
radiation therapy according to the American Joint Committee on
Cancer (7th edition) with computed tomography of the chest, abdomen,
and pelvis. After November 2011, protocol amendment was approved
to exclude those patients with nodal or metastatic disease.
y Includes variant transitional cell carcinomas.
z No patient had performance status >3 at baseline assessment; 17
patients did not have performance status documented at baseline
assessment but were deemed fit for proposed treatment by recruiting
clinician (ie, presumed performance status 0-3).
x Modified Charlson-Deyo score (measure of comorbidity across
multiple organ sites, captured using International Classification of
Diseases, 9th revision, Clinical Modification codes) was retrospec-
tively calculated for each patient excluding his or her diagnosis of
bladder cancer at presentation. Age-adjusted Charlson index score: for
each decade after 40 years an additional point is added.
k Three patients were planned to 30 Gy in 5 fractions because of
either advanced disease or limited performance status; 48 patients
completed their prescribed course of radiation therapy.
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Patient characteristics are shown in Table 1. Target
coverage and normal tissue sparing have been previously
presented (12). Seven patients stopped treatment early
because of deterioration in their general health. Four deaths
occurred during radiation therapy unrelated to treatment
(3 from pneumonia and 1 from urinary sepsis).
Treatment-related toxicity
Radiation therapy was well tolerated, with no grade 4
genitourinary or gastrointestinal toxicity seen at any time.
At baseline (before radiation therapy), grade 2 and grade
3 urinary toxicity was evident in 10 (19%) and 5 (9%)
patients. During treatment, acute genitourinary grade 2 and
grade 3 toxicity was seen in 22 (40%) and 10 (18%) pa-
tients, respectively (Fig. 1). At 6 weeks after radiation
therapy, 8 patients (20% of those assessed) had grade 2
urinary toxicity, and 2 patients (5% of those assessed) had
grade 3 urinary toxicity. At 12 weeks after radiation therapy
6 patients (27% of those assessed) reported grade 2 toxicity,
and 1 patient (4.5% of those assessed) had grade 3 urinary
toxicity.
Acute gastrointestinal grade 2 and grade 3 toxicity was
seen in 21 (38%) and 2 (4%) patients, respectively. Change
in acute toxicity over time is shown in Figure E1 (available
online at www.redjournal.org). Figure E2 (available online
at www.redjournal.org) shows total number of patients
available for assessment at each time point.
Other acute grade 2 toxicity occurred in 23 (42%) pa-
tients (predominately fatigue or anemia). Other acute grade
3 toxicity occurred in 2 (4%) patients (hyponatremia and
syncope). One grade acute 4 toxicity event occurred (ven-
tricular arrhythmia), unrelated to radiation therapy. No
known radiation therapy treatment-related deaths occurred
during the follow-up period.
The RTOG late toxicity scores at 6 and 12 months were
available for 31 and 23 patients, respectively. Grade 2 late
toxicity of any type at 6 and 12 months was seen in 6/31
(19%) and 3/23 (13%) patients, respectively. Grade 3 late
toxicity of any type at 6 and 12 months was seen in 2/31
(6.5%) and 1/23 (4.3%) patients, respectively (Fig. 2). At
6 months, 5 patients (16.1%) reported grade 2 and 2 pa-
tients (6.5%) reported grade 3 RTOG bladder toxicity. At
12 months, 2 patients (8.7%) reported grade 2 and 1 patient
(4.3%) reported grade 3 RTOG bladder toxicity. All late
bladder symptom scoring (grade 2 and grade 3) were as a
result of cystitis-like symptoms (frequency, urgency, and
dysuria). No episodes of grade 2 hematuria were reported
at 6 or 12 months.
No 3 grade late bowel toxicity was seen. Two patients
experienced grade 2 toxicity at 6 months (6.5%), and 1
patient (4.3%) had grade 2 toxicity at 12 months. All late
RTOG bowel symptoms (scoring at grade 2) were as a
result of diarrhea.
Fig. 1. Worst symptoms or acute toxicity as graded by the Common Terminology Criteria for Adverse Events CTCAE
version 3.0. Total number of patients available for assessment at each time point experiencing any toxicity: before radiation
therapy (RT), 55; RT week 1, 54; week 2, 53; week 4, 49; week 5, 49; week 6, 45; 6 weeks after RT, 41; 12 weeks after RT,
23. Abbreviations: GI Z gastrointestinal; GU Z genitourinary.
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Response to radiation therapy 3 months after completing
treatment was assessed in 36 patients. This was performed
by cystoscopy in 30 patients. Thirty-three of 36 (92%) of
assessed patients (60% of all patients) achieved local dis-
ease control within the bladder at 3 months, and 28/30
(93%) achieved complete response as assessed by cystos-
copy. This means that local control at 3 months was ach-
ieved in a minimum of 51% (28/55) of all patients (based
on assuming failure in all patients not assessed by cystos-
copy). Cumulative incidence of local progression was 7%
(95% confidence interval [CI] 2%-17%) and 17% (95% CI
8%-29%) for all patients at 1 year and 2 years, respectively.
Results for patients stratified by stage are presented in
Figure 3.
After a median follow-up time of 2 years, a total of 38
deaths were recorded. Estimated survival at 1 year was 62%
(95% CI 48%-74%) (Fig. 4). Table 2 summarizes the out-
comes grouped by stage.Discussion
Our study demonstrates that patients with high median age
and comorbidity index who are deemed unsuitable for
radical treatment can be treated with hypofractionated
weekly radiation therapy delivered with a plan of the day
approach with acceptable morbidity rates.
Given cancer-specific mortality is highest in individuals
older than 80 years, the assumption that death resulting from
competing medical conditions rather than from MIBC jus-
tifies no active treatment does not necessarily hold true (2).
Intervention (cystectomy, radiation therapy, or transurethral
resection alone) for older patients significantly reduces risk
of death from MIBC compared with watchful waiting (2, 3).
Watchful waiting alone, we contend, also would have been
suboptimal management, given that 85% of our patient
population had potentially curable disease (T2 or T3 only
disease). Our data also support intervention for this popula-
tion, as long-term survival and progression-free survival was
achieved in a third of patients.
Fig. 2. Worst late toxicity at 6 and 12 months as graded by Radiation Therapy Oncology Group (RTOG). Total number of
patients available for assessment at each time point experiencing late toxicity: 6 months, 31; 12 months, 23.
Fig. 3. Cumulative incidence of local progression using death resulting from other causes as competing risk, for all patients
and stratified by stage. Abbreviation: CI Z confidence interval.
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Fig. 4. Kaplan-Meier plots for rates of overall survival and stratified by stage. Abbreviation: CI Z confidence interval.
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is approximately 48 Gy, assuming a/b of 10 for tumor
control when delivered in 2 Gy per fraction (EQD2). ItTable 2 Status at last follow-up visit after median follow-up time o
Status
Number o
Initial
T2N0M0
Initial
T3-T4N0
Alive 12 5
Disease free 10 5
Localized disease (bladder) 1 0
Regional disease (pelvis) 0 0
Metastases 1 0
Dead 24 9
Metastases 10 4
Other malignancy 1 1
Other causes* 13 4
* No known deaths resulting from radiation therapy occurred; 19 other causes
sepsis (2 patients), unknown cause of death (2 patients), sepsis from idiopathic
disease (1 patient), superior vena cava obstruction (1 patient).delivers a higher total dose than other commonly used ra-
diation therapy regimens in the nonradical setting. The
EQD2 of 20 Gy in 5 fractions, 21 Gy in 3 fractions, andf 2 years
f patients
Total patient number (%)M0
Initial
TanyN þ M1
0 17 (30.9)
0 15 (27.3)
0 1 (1.8)
0 0 (0)
0 1 (1.8)
5 38 (69.0)
3 17 (30.9)
0 2 (3.6)
2 19 (34.5)
of death were pneumonia (8 patients), cardiac events (4 patients), urinary
myelosuppression and bowel obstruction (1 patient), peripheral vascular
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respectively. Although fewer fractions are less burdensome,
to achieve balance between efficacy, toxicity, and conve-
nience, patients’ prescriptions should be individualized.
Turgeon et al (18) delivered 50 Gy in 20 fractions
with non-IGRT intensity modulated radiation therapy,
achieving EQD2 of 52 Gy. Their patients (median age,
70) were also suitable for concurrent chemotherapy
(gemcitabine), which clinically improves local control and
from radiobiological modeling has equivalent additional
>10 Gy benefit (19). They achieved 83% complete
response, 43% of which had assessment with cystoscopy
and biopsy.
Biopsy assessment was not mandated within our study
because that would have necessitated rigid cystoscopy and
the use of anesthetic agents in a high-risk population. The
absence of pathologic correlation (biopsy at the time of
cystoscopy) lends itself to tumor understaging; however,
any downstaging achieved (ie, partial response) has po-
tential patient benefit (20).
Even though most patients (72%) had no significant
urinary symptoms (grade 0-1) before receiving radiation
therapy, urinary symptom scores did not deteriorate during
radiation therapy, as may have been anticipated, given
improved targeting with the plan of the day approach (12).
There is some suggestion of possible improvement in
scores after radiation therapy than at baseline, reflecting
potential early symptom control.
Given that 1-year survival is 62% (95% CI 48%-74%);
the risk of late toxicity is an important consideration,
especially in the context of the large fraction size used, but
the observed rate of late toxicity (grade 2) was low. The
dosimetric advantage with plan of the day is likely to have
contributed to both the high complete response and the low
nonurinary toxicity rates (12). We acknowledge that owing
to the nature of the trial population, a proportion of patients
did not contribute toxicity information. Such missing data
are inevitable, and illustrates the difficulties of assessing a
less fit population.
A weakness of this work is that it is a single-center
single-arm study. We shall address this within a randomized
multicenter trial (HYBRID study; hypofractionated bladder
radiation therapy with or without image guided adaptive
planning NCT01810757) (17). Unlike the reported phase 2
study, this trial will allow treatment delivery using volu-
metric intensity modulated arc therapy. In addition to
improving conformity, it will shorten treatment delivery
time, thereby reducing the opportunity for intrafraction
organ motion and filling (21). Further opportunity to spare
normal tissue is likely to come from online reoptimization
strategies in development (22).
In conclusion, hypofractionated bladder radiation ther-
apy of 36 Gy in 6 weekly fractions delivered with image
guidance presents an important disease control option in
appropriately selected patients and meets the clinical need
for a somewhat neglected patient population. Exclusion
from radical treatment on the basis of age alone would beunacceptable because functional decline is specific to the
individual. This approach is advocated not as an alternative
to radical treatment but as a means of potential disease
control in patients with competing comorbidities.
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